#CardiometabolicDiseases
LightNews LightNews
pharmaphorum.bsky.social
#EliLilly's triple G agonist #retatrutide has achieved impressive #weightloss in patients with #type2diabetes and #obesity, boosting its credentials as the next big thing in #cardiometabolicdiseases.

pharmaphorum.com/news/lilly-f...
September 30, 2026 at 11:24 AM
pharmaphorum.bsky.social
The latest round of R&D funding from the #NovoNordiskFoundation has been announced and will go towards projects in #biomanufacturing, #cardiometabolicdiseases, and #artificialintelligence.
Novo Nordisk Foundation gives $75m for R&D 'challenges'
The Novo Nordisk Foundation's latest round of R&D funding will go towards projects in biomanufacturing, cardiometabolic diseases, and AI.
buff.ly
June 27, 2025 at 1:00 PM
bionewscentral.com
New research finds that #GutBacteria can convert #DietaryNitrate and #iron into protective molecules that may reduce the risk of #CardiometabolicDiseases.
#GutMicrobiome
Gut bacteria convert dietary nitrate and iron into protective molecules – BioNews Central
New research finds that gut bacteria can convert dietary nitrate and iron into protective molecules that may reduce the risk of cardiometabolic diseases. ...
sbee.link
August 20, 2026 at 3:20 PM
pharmaphorum.bsky.social
#ScribeTherapeutics has become the latest #biotech to list on the #Nasdaq in the US, raising more than $155 million to advance a pipeline of in vivo #CRISPR-based therapies for #cardiometabolicdiseases.
Scribe raises $155m in IPO, as Apnimed pitches for $150m
Gene-editing specialist Scribe becomes the 14th biotech to list on the Nasdaq this year, as sleep apnoea drug developer Apnimed prices its listing.
buff.ly
July 28, 2026 at 11:30 AM
infectiousdisease.bsky.social
People with #HIV who have never been on #AntiRetroviralTherapy have a notable prevalence of #CardiometabolicDiseases, indicating a cardiometabolic burden is present prior to ART initiation.
Read more ⬇️
https://www.infectiousdiseaseadvisor.com/news/cardiometabolic-diseases-burden-antiretrovirals-hiv/
June 17, 2026 at 9:45 PM
jcst2d.bsky.social
Novo Nordisk and Valo Health expand their AI partnership to accelerate treatments for obesity, diabetes, and cardiovascular diseases, increasing programs from 11 to 20 using Valo's Opal Platform.

jcst2d.com/index.php?vi...

#NovoNordisk #ValoHealth #AI #CardiometabolicDiseases #OpalPlatform
Logos of Novo Nordisk and Valo Health side by side. The Novo Nordisk logo features a stylized blue bull with the company name below, while the Valo logo includes a simple black outlined circle above the company name in a clean font.
January 23, 2025 at 2:40 AM
4040rec.bsky.social
#Obesity #cardiometabolicdiseases #earlyphaseresearch #clinicaltrialdesign #clinicaldevelopment #clinicaltrialsponsors #weightloss #obesitydrivencomorbidities #GLP1receptoragonists #MASLD #patientrecruitment #Personalisedtrialdesign #obesitytrials #cardiometabolicsector
zurl.co/ErmB8
Obesity, complexity, and the lab: What 2025 taught us, and what comes next
The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.
pharmaphorum.com
January 21, 2026 at 11:56 AM
jcsanalytics.bsky.social
Novo Nordisk and Valo Health expand their AI partnership to accelerate treatments for obesity, diabetes, and cardiovascular diseases, increasing programs from 11 to 20 using Valo's Opal Platform.

jcsanalytics.com/index.php?vi...

#NovoNordisk #ValoHealth #AI #CardiometabolicDiseases #OpalPlatform
Logos of Novo Nordisk and Valo Health side by side. The Novo Nordisk logo features a stylized blue bull with the company name below, while the Valo logo includes a simple black outlined circle above the company name in a clean font.
January 23, 2025 at 2:24 AM